The world after covid 197/4/2023 That’s because they became so pervasive during the pandemic for deliveries, COVID-19 tests, automated services and even home use. Robin Murphy, engineering professor at Texas A&M University, is convinced that “we are going to have robots everywhere” as a result of COVID-19. Not all turbulence, however, is unwelcome.Īcross sectors, expert after expert told me that habits developed during the pandemic won’t go away – and not just the habits of Zoom and working from home. COVID-19 accelerated and intensified this great power rivalry with ramifications across Asia, Europe, Africa, Latin America and the Middle East. Geopolitically, this manifests itself in what the founding dean of Harvard’s Kennedy School, Graham Allison, calls an “underlying, fundamental, structural, Thucydidean rivalry” in which a rapidly rising new power, China, threatens to displace the established power, the United States. None of our experts – not one – expects politics anywhere to become less turbulent than it was pre-pandemic. Stanford University’s political theorist Francis Fukuyama confesses he has “never seen a period in which the degree of uncertainty as to what the world will look like politically is greater than it is today.”ĬOVID-19 has underscored fundamental questions about government competence, the rise of populist nationalism, sidelining of expertise, decline of multilateralism and even the idea of liberal democracy itself. While the clouds over the global economy are ominous – with even the usually optimistic Nobel Prize-winning economist Sir Angus Deaton worrying we might be entering a dark phase that takes “20 to 30 years before we see progress” – it is political commentators who seem most perplexed. And Pardee School economist Perry Mehrling is convinced that “society will be transformed permanently … and returning to status quo ante is, I think, not possible.” Politics will become more turbulent Pulitzer Prize-winning editor Ann Marie Lipinski arrives at the same prognosis for journalism, and Princeton economist Atif Mian worries similarly for structural global debt.Īt Harvard, trade policy expert Dani Rodrik thinks the pandemic is hastening the “retreat from hyperglobalization” that was already in train before COVID-19. As Eurasia Group President Ian Bremmer highlights, a year of a global pandemic can pack in a decade or more of disruption as usual.įor example, Phil Baty from “Times Higher Education” warns that universities will change “profoundly forever,” but mostly because the higher education sector was already screaming for change. Just as people with preexisting medical conditions are most susceptible to the virus, the global impact of the crisis will accelerate preexisting transitions. Our pre-pandemic world was anything but normal, and our post-pandemic world will not be like going back to normal at all. Among other things, it helped me understand why COVID-19 is not a storm that we can just wait out. Secretary General Ban Ki-moon joined from Seoul.įor me, it was truly a season of learning. I “Zoomed” – the word had become a verb almost overnight – with Kishore Mahbubani in Singapore, Yolanda Kakabadse in Quito, Judith Butler in Berkeley, California, Alice Ruhweza in Nairobi and Jeremy Corbyn in London. National Academy of Sciences, a former CIA director, a former NATO supreme allied commander, a former prime minister of Italy and Britain’s astronomer royal. Goldberg denied the motion for a second time last month after the federal government backed Moderna's position.My interviewees included the president of the U.S. District Judge Mitchell Goldberg rejected Moderna's motion in that case last year and said it had not yet proven the government was more than an "incidental beneficiary" of the shots. Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp and Genevant Sciences GmbH. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One. government and that Alnylam should instead seek damages from the government itself. Moderna said in the Alnylam case that the court should dismiss claims that were based on vaccines it sold to the U.S. The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year. Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA.
0 Comments
Leave a Reply. |